中文 | ENG

第57卷 第6期 2024-11
Emerging robot-guided techniques in endodontic microsurgery

.........................

第57卷 第6期 2024-11
Management of subcapsular hematoma after living donor liver transplant

.........................

第57卷 第6期 2024-11
Urethral pseudodiverticulum with left-sided nonfunctioning kidney: Case report

.........................

第57卷 第6期 2024-11
Strategy to minimize surgical defect of dermatofi brosarcoma protuberans

.........................

第57卷 第6期 2024-11
Rapunzel syndrome—An uncommon disease with varied common presentations

.........................

第57卷 第6期 2024-11
Minimally invasive approaches to management of acute necrotizing pancreatitis

.........................

第57卷 第6期 2024-11
Innovative surgical technique: Addressing ethical concerns

.........................

第57卷 第6期 2024-11
Emergency surgery and HIV screening, clinical or universal scenarios?

.........................

第57卷 第6期 2024-11
High mortality rates associated with parainfl uenza virus, not metapneumovirus, infections in lung transplant recipients: A retrospective observation

.........................

第57卷 第6期 2024-11
Predatory clinical surgery journal, rescinding the decision to accept submitted article and unjustifi ed rejection and unprofessional conduct

.........................

第57卷 第6期 2024-11
Sacrifi cial of unilateral vertebral artery for fragment removal following vertebral artery injury by air rif le pellet gunshot: A case report

.........................

第57卷 第6期 2024-11
Evaluation of three-dimensional reconstruction technology in precision hepatectomy for primary liver cancer

.........................

第57卷 第6期 2024-11
Exploring the seasonal variation of anorectal disease: A comprehensive study

.........................

第57卷 第6期 2024-11
Efficacy of the minimal-invasive vacuum-assisted biopsy under direct visualization with ultrasound for impalpable breast lesions in Taiwanese female: A retrospective case-control study

.........................

第57卷 第6期 2024-11
Computed tomography on the 5th postoperative day helps distinguish grade C from grade B pancreatic fi stula after pancreaticoduodenectomy for periampullary cancer

.........................

第57卷 第6期 2024-11
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Why it will transform cancer surgery

.........................

第57卷 第5期 2024-9
Evaluating the pros and cons of anonymous commenting on PubPeer

.........................

第57卷 第5期 2024-9
Infected urachal cyst with urethral stricture disease presenting with intraperitoneal perforation of cyst and pyoperitoneum

.........................

第57卷 第5期 2024-9
COVID-19 vaccination and acute cholecystitis: A rare but important clinical problem

.........................

第57卷 第5期 2024-9
Hobnail-shaped primary prostatic urethral calculus due to urethral stricture disease

.........................
登入帳號才能閱讀全文
 
篇名 Screening for Ocular Toxicity in Asymptomatic Patients Treated with Tamoxifen
作者 Jie-Jen Lee, Po-Sheng Yang, Chih-Chun Lu, Tsen-Long Yang, Chien-Liang Liu, Ai-Ching Wu
卷期/出版年月 30卷2期 (1997/4)
頁次 98-102
摘要 Tamoxifen is the drug of choice in the initial hormonal treatment for both premenopausal and postmenopausal women with ER-positive breast car-cinoma. Generally, the drug is well tolerated, although case reports have documented ocular toxicity in patients receiving very-high-dose tamoxifen >180 mg/d). The ocular side effects include corneal changes, optic neuritis, retinopathy, and macular edema. As the currently recommended dose of the drug is 20 mg per day, we attempted to determined the prevalence of ocular toxicity in patients treated with such a low daily dose of tamoxifen. This study included 75 breast cancer patients who had been treated with tamoxifen for variable periods of duration after surgical intervention and who had undergone ocular examinations before any visual symptoms had appeared. The mean duration of tamoxifen treatment was 16.2 months (range 2-49 months). The mean cumulative dose of the 75 patients was 9.7+ 6.6 gm (range 1.2-31.8 gm). No tamoxifen-related ocular toxicity was noted the in our study. Although our data showed no tamoxifen ocular toxicity in asymptomatic patients during the course of current tamoxifen therapy, ocular safety of higher cumulative dosages recommended by conventional Thus, therapy is still unknown. all physicians should still be aware of the potential of ocular toxicity associated with tamoxifen and encourage baseline ophthalmologic evaluations and close monitoring of any ocular complaints that might arise during therapy. If any ophthalmic complica-tions should occur, tamoxifen should be discontinued immediately. It is important to keep in mind that even low dose tamoxifen can induce ocular toxicity. The potential ocular toxicity of tamoxifen, even at low doses, can by no means be overlooked.
關鍵詞 tamoxifen, ocular toxicity, breast cancer
分類 Original Article

台灣外科醫學會雜誌 © 2006 Taiwan Surgical Association All Rights Reserved
會 址:台北市南京東路五段 31 號 3 樓
電 話:(02) 2769-7845 傳 真:(02) 2746-7149 Email: journal@surgery.org.tw